Clinical pharmacology of levodopa-induced dyskinesia

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Nutt, John G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DENERVATION; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG SENSITIZATION; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034027839     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neural 2000;47(suppl 1):S2-S11
2. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 1971;12(Part 2):340-343
3. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesia in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673
4. Chase TN, Holden EM, Brody JA. Levodopa-induced dyskinesias: comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol 1973;29:328-330
5. Barbeau A, Mars H, Gillo-Joffroy L. Adverse clinical side effects of levodopa therapy. In: McDowell FH, Markham CH, eds. Recent advances in Parkinson's disease. Philadelphia: F.A. Davis Co., 1971:204-237
6. Rajput AH, Fenton ME, Birdi S, Maculay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638
7. Boyce S, Rupnaik NMJ, Steventon MJ, Iverson SD. Nigrostriaral damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;5:448-458
8. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196
9. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated patients. Ann Neurol 2000;47(suppl 1): S90-S104
10. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44
11. van Horne C, Hoffer BJ, Strömberg I, Gerhardt GA. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J Pharmacol Exp Ther 1992;263: 1285-1292
12. Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997;12:629-633
13. Weiner WJ, Sanchez-Ramos J. Movement disorders and dopaminometic stimulant drugs. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisco: Futura Publ. Co., 1992:315-337
14. Langston WJ, Ballard P. Parkinsonsim induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984;11:160-165
15. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226
16. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378
17. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130
18. Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997;42:349-355
19. Clarke CE, Boyse S, Sambrook MA, Crossman AR. Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet 1987;2:625
20. Pearce RK, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740
21. Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985;232:29-31
22. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited - clinical features, natural history and mortality. Mov Disord 1998;13:885-894
23. Block GA, Liss CL, Reines S, et al. CR First Study Group. Comparison of immediate-release and controlled release carbidop/levodopa in Parkinson's disease. Eur Neurol 1997;37: 23-27
24. Szechtman H, Talangbayan H, Canaran G, et al. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology 1994;115:95-104
25. Kuczenski R, Segal DS. Psychomotor stimulant-induced sensitization: behavior and neurochemical correlates. In: Kalivas PW, Barnes CD, eds. Sensitization in the nervous system. Caldwell, NJ: Telford Press, 1988:177-205
26. Post RM. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci 1980;26:1275-1282
27. Castro R, Abreu P, Calzadilla CH, Rodriquez M. Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacology 1985;85:333-339
28. Colosimo C, Merello M, Hughes AJ, et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;61:634-637
29. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371
30. Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44:1287-1292
31. Casey DE. Neuroleptic-induced parkinsonism increases with repeated treatment in monkeys. Psychopharmacol Ser 1987;3: 243-247
32. Nutt JG, Carter JC, Woodward WR. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 1994;44: 1617-1622
33. Vaamonde J, Luquin MR, Obeso JA. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease. Clin Neuropharmacol 1989;12:271-284
34. Grandas F, Obeso JA. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neuropharmacol 1989;12:14-22
35. Cedarbaum JM, Clark M, Toy LH, Green-Parsons A. Sustained-release of (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation. Mov Disord 1990;5:298-303
36. Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991;54:358-360
37. Gancher ST, Nutt JG, Woodward WR. Time-course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52: 504-510
38. Clarke CE, Boyce S, Robertson RG, et al. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intra carotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1989;90:307-314
39. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279
40. Blanchet PJ, Grondin R, Bédard PJ. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 1996;11:91-94
41. 2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413
42. Coleman RJ, Quinn NP, Traub M, Marsden CD. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:102-105
43. Rascol O, Blin O, Descombes S, et al. ABT-431, a selective D1 agonist, has efficacy in patients with Parkinson's disease. Neurology 1997;48(Suppl):A269-A270 (Abstract)
44. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276: 374-379
45. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S179-S188
46. Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997; 337:1036-1042
47. Samuel M, Caputo E, Brooks DJ, et al. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI localization and complications. Brain 1998;121:59-75
48. Bejjani B, Damier P, Arnulf I, et al. Pallidal stimulation for Parkinson's disease: two targets? Neurology 1997;49:1564-1569
49. Krack P, Pollak P, Limousin P, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998;43: 180-192
50. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744
51. Merman LV, van den Mundkhof P, Klaassen AAG, et al. Effects of supra-threshold levodopa doses on dyskinesia in advanced Parkinson's disease. Neurology 1997;49:711-713
52. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesia in Parkinson's disease. Ann Neurol 1989;25:523-526
53. Nutt JG, Gancher ST, Woodward WR. Motor fluctuations in Parkinson's disease. Ann Neurol 1987;25:633
54. Contin M, Riva R, Martinelli P, et al. Relationship between levodopa concentration, dyskinesias and motor effect in parkinsonian patients: a 3-year follow-up. Clin Neuropharmacol 1997; 20:409-418
55. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394